Biologics Safety Testing Market to Perceive Momentous Accruals with a hefty CAGR By 2023

 Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Biologics Safety Testing Market Research Report - Forecast to 2023” Gives industry size, top players and worldwide demand

Biologics Safety Testing Market Analysis 

Global biologics safety testing market is predicted to expand at a 13.6% CAGR between 2018-2023, reveals the new Market Research Future (MRFR) report. Biological safety testing is conducted to ensure both the non-contamination and safety of biopharmaceuticals and vaccines and also comply with its regulations. Bioburden tests, adventitious agent detection tests, residual host contamination detection tests, cell line authentication & characterization tests, endotoxin tests, sterility tests, and others are some major biological tests. It is used in stem cell research, tissue & tissue-related products testing, cellular & gene therapy, blood & blood-related products testing, and vaccine & therapeutics development.

Also Read : https://www.medgadget.com/2020/03/biologics-safety-testing-market-to-grow-at-13-6-cagr-by-2023-americas-to-command-largest-share-in-biologics-safety-testing-industry.html 

Numerous factors are adding to the global biologics safety testing market growth. Such factors, as revealed by the recent MRFR report, include growing demand for biological products, growing biotech and pharmaceutical industry, rising number of innovative drug launches, and high prevalence and huge economic burden of various chronic diseases. Increasing research and development investment in life science and favorable government support are also adding market growth.

On the contrary, high investment costs related to biological safety cabinets, time-consuming approval process, stringent government regulations, and scarcity of skilled professionals to conduct biological safety testing are factors that may limit the biologics safety testing market growth during the forecast period. 

Biologics Safety Testing Market Key Players

Leading players profiled in the global biologics safety testing market report include

• Eurofins Scientific
• Avance Biosciences Inc.
• Cytovance Biologics Inc.
• Wuxi Apptec
• Thermo Fisher Scientific Inc
• SGS S.A.
• Lonza Group Ltd.
• Sartorius AG
• Charles River Laboratories
• Merck KGaA

Biologics Safety Testing Market Segmentation

The Market Research Future Report provides an inclusive segmental analysis of the biologics safety testing market based on application, test type, and product.

By product, the biologics safety testing market is segmented into instruments, services, and kits & reagents. Of these, kits and reagents will lead the market over the forecast period.

By test type, the biologics safety testing market is segmented into bioburden tests, adventitious agent detection tests, residual host contamination detection tests, cell line authentication & characterization tests, endotoxin tests, sterility tests, and others. Of these, endotoxin tests will dominate the market over the forecast period for increasing drug launches and rising disease prevalence. This testing is used in drug development, gene therapy, vaccine testing, monoclonal antibody testing, and cell therapy.

By application, the biologics safety testing market has been segmented into stem cell research, tissue & tissue-related products testing, cellular & gene therapy, blood & blood-related products testing, and vaccine & therapeutics development. Of these, vaccine & therapeutics development will have a major share in the market over the forecast period for rising company investments to develop vaccines, growing initiatives for immunization, and increasing prevalence of diseases.

Biologics Safety Testing Market Regional Analysis

By region, the biologics safety testing market covers the growth opportunities and recent trends across Europe, the Americas, the Middle East & Africa (MEA), and the Asia Pacific (APAC). Of these, the Americas will command the largest share in the market over the forecast period. Factors adding to the biologics safety testing market growth in the region include growing demand for biological products, new product launches, presence of well-established players, and growing pharmaceutical and biotechnology industries. Additional factors adding market growth include favorable government initiatives, rising R&D spending, and advanced healthcare infrastructure.

The global biologics safety testing market in Europe is predicted to hold the second-largest share during the forecast period for the growing biotech and pharma industry.

The biologics safety testing market in the APAC region is predicted to grow at a quick pace during the forecast period for the burgeoning demand for biologics products.

The biologics safety testing market in the MEA will have a small share over the forecast period. The Middle East will have major share for the presence of a well-established healthcare sector.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biologics-safety-testing-market-6800 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Stem Cell Assay Market | Worldwide Top key Players Profile Analysis | Forecast till 2023

 Market Research Future adds the “Stem Cell Assay Market Research Report - Forecast to 2023” report to their unique collection.

Stem Cell Assay Market Scenario

Global stem cell assay market 2020, according to MRFR, is expected to witness substantial growth over the review period.

Stem Cell Assay Market  Highlights

Stem cell assays are an integral aspect of the field of biotechnology, which is increasing. The prevalence of chronic and various lifestyle disorders has forced drug research efforts to intensify in an attempt to create innovative therapies. Diseases like cancer and diabetes are on the increase at fast levels, and demand for safer, more effective, and more affordable drugs is pushing the industry towards expansion. Global health care spending is growing, and demand growth is strongly supported by developments in biotechnology and other medical innovations. Policy funding to the production of medications for chronic disorders has expanded work into stem cell assays.

Also Read : https://www.medgadget.com/2020/09/stem-cell-assay-market-size-is-estimated-to-grow-at-a-cagr-of-19-80-by-2023-global-industry-share-grwoth-analysis-new-technology-developments-top-company-profile-revenue-applications.html

Strict regulatory regulations related to drug clearance, as well as high clinical costs of stem cell assays, hold the industry hostage. Also, there is a lack of knowledge about stem cell assays, and as a result, there is a shortage of qualified practitioners that hinders market development. However, rising healthcare practices and the growing need for therapy are expected to put stem cell assays to the forefront, and there are plenty of opportunities on the market.

Stem Cell Assay Market Segmental Analysis

The global stem cell assay market is analyzed based on the technology, product, assay, application, and end-user.

Based on the product, the market is segmented into automated cell counter, microelectrode arrays, flow cytometer, cell imaging systems, kits, and others. The kits segment is sub-segmented into mesenchymal stem cell kits, induced pluripotent stem cell kits, umbilical cord stem cells, and others.

Based on the technology, the market is segmented into microfabricated assisted technology microfluidics-based cell trap technologies, and others.

Based on the assay, the market is segmented into cell viability & toxicity assays, cell identification assays, cell proliferation assays, cell apoptosis assays, and others.

Based on the application, the market is segmented into the orthopedic & musculoskeletal spine, dermatology, cardiovascular, central nervous system, and others.

Based on the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.

Stem Cell Assay Market Regional Overview

The Americas are leading the global stem cell assay industry as an emerging technology, and a large patient pool is gradually being embraced for diseases such as diabetes, cancer, and others. Besides, healthcare spending is driving demand growth with the involvement of advanced economies such as the U.S. and Canada within the region.

Owing to the rising biotechnology industry and massive patient population, the global stem cell assay market in Europe is the second-largest. Growing policy funding for research and development, in turn, promotes business demand. The UK is the fourth biggest donor worldwide to biotechnology research and development.

Asia Pacific area is the fastest growing stem cell assay market in the world due to increased awareness and higher healthcare spending. Also, the emergence of emerging economies such as India and China has an expanding biotechnology industry that fuels demand growth.

Middle East & Africa has the least share on the global stem cell assay market due to low per capita healthcare spending, lack of understanding, strict government policies, and the prevalence of weak economies , particularly in the African region. In Middle East & Africa the Middle East has a lot of stem-cell assay industry. A well-developed healthcare system and massive investment in healthcare through the involvement of developing economies such as Saudi Arabia, Kuwait, and Qatar within the country fuel the region’s business growth.

Stem Cell Assay Market Competitive Dashboard

The eminent market players fo the global market are Promega Corporation (U.S.), Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), Cell Biolabs, Inc. (U.S.), STEMCELL Technologies Inc. (CA), Bio-Rad Laboratories, Inc. (U.S.), Hemogenix (U.S.), GE Healthcare (U.K.), Bio-Techne Corporation (U.S.), and Cellular Dynamics International Inc. (U.S.), and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/stem-cell-assay-market-5656 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Worldwide Medical Carts Market Ready To Set Outstanding Growth From 2020 To 2023

 

Market Highlights

The growing acceptance of medical carts accustomed by its technical advances is one of the major trends witnessed in the global medical carts market over the forecast period.

According to world health organization, musculoskeletal conditions are the second largest contributor to disability globally. Musculoskeletal conditions include conditions that affect joints (psoriatic arthritis, gout, osteoarthritis, rheumatoid arthritis), bones (osteoporosis, osteopenia and associated fragility fractures), and muscles (sarcopenia).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7436 

Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as high cost of advanced medical carts in developing countries, is likely to curb the market growth during the forecast period.

Key Players

Some of the global medical carts market manufacturers are ITD GmbH (Germany), Advantech Co. (Taiwan) Ltd, Harloff Manufacturing Co. (US), AFC Industries (US), Chang Gung Medical Technology Co. (Taiwan), Omnicell Inc. (US), Midmark Corporation (US), The Bergmann Group (US), Capsa Healthcare (US), Jaco Inc (US), Waterloo Healthcare (US), Ergotron Inc (US) and others.

Segmentation

The global medical carts market is segmented based on product type, type, material type, and end-users.

The medical carts market, by product type, the market is segmented into mobile computing carts, medical storage columns, wall-mounted workstations, medication carts, and others.

Based on type, the market is segmented into computer medical cart, procedure cart, emergency cart, anaesthesia cart, and others.

Based on material type, the market is segmented into metal type, plastic type, and others.

 Based on end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, and others.

Regional Analysis

The Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians. It is currently exhibiting a highly lucrative growth rate due to an increased use of medical carts for various applications. 

The European region is the second largest medical carts market over the forecast period due to high acceptance of medical carts in developing countries along with the rising incidence of chronic diseases are also accountable for the growth of the medical carts market.   

The Asia Pacific region is likely to develop at the uppermost CAGR for the medical carts market in the years to come. Moreover, the rising patient safety at the hospitals and at community level are expected to influence the market in a positive way.

The Middle East and Africa accounts for the least market share due to low per capita income and lack of availability of well-trained healthcare professionals. 

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/medical-carts-market-7436 

The Veterinary Laboratory Testing Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights

The global veterinary laboratory testing market is expected to grow at a CAGR of 10.1% during the forecast period.

Increasing expenditure on pet insurance, growth in the number of veterinary practitioners, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.

However, high cost of veterinary testing and complications associated with the tests can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7326 

Regional Analysis

Geographically, the Americas is anticipated to dominate the global veterinary laboratory testing market owing to the increasing cases of animal disease and technological advancements in veterinary diagnostics. For instance, in 2016, IDEXX Laboratories, Inc. launched the Rapid Visual Pregnancy Test for cattle. With the new test, veterinarians can more quickly identify open cows using whole blood samples collected before the farm visit. Europe is expected to hold the second largest position in the global veterinary laboratory testing market. The market growth in this region is attributed to the rising expenditure on pet insurance. The Veterinary Laboratory Testing Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the awareness regarding use of sterile consumables for lab testing and rising healthcare spending. The Middle East & Africa contributes least in the global market for veterinary laboratory testing.

Key Players

Some of the global veterinary laboratory testing market companies are Abaxis, Inc., BIOCHECK Inc., Biomérieux SA, Henry Schein, Inc., Heska Corporation, Idexx Laboratories, Idvet, Neogen Corporation, Pfizer, Qiagen N.V., Randox Laboratories, Ltd., Thermo Fisher Scientific, VCA Inc., Virbac, Zoetis, Inc. and others.

Segmentation

The global veterinary laboratory testing market has been segmented into animal type, technology, product, and end user.

The market, on the basis of animal type, has been segmented into companion animal and livestock animal. The companion animal segment is further classified as dogs, cats, horses and others. The livestock animal segment is further classified as cattle, pigs, poultry and others.

The market, by technology, has been segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others.

The clinical biochemistry segment is further classified as clinical chemistry analysis, glucose monitoring, and blood gas & electrolyte analysis. The clinical chemistry analysis segment includes clinical chemistry reagent clips and cartridges and clinical chemistry analyzers. The glucose monitoring segment includes blood glucose strips, glucose monitors and urine glucose strips. The blood gas & electrolyte analysis segment includes blood gas and electrolyte reagent clips and cartridges and blood gas & electrolyte analyzers.

The immunodiagnostics segment is further classified as ELISA tests, lateral flow assays, allergen-specific immunodiagnostic tests, immunoassay analyzers, and others. The lateral flow assays segment includes lateral flow rapid tests, and lateral flow strip readers.

The hematology segment is further classified as hematology cartridges, and hematology analyzers.

The molecular diagnostics segment is further classified as polymerase chain reaction (PCR) tests, microarrays, and others.

The urinalysis segment is further classified as urinalysis clips & cartridges/panels, urine analyzers, and urine test strips.

The market, by product, has been segmented into consumables and instruments.

The market, by end user, has been segmented into veterinary hospitals & clinics, in-house testing, research institutes, diagnostic laboratories, and others. The veterinary hospitals & clinics segment held the largest segment of the market in 2017. This can be attributed to the increasing incidence of zoonotic diseases. On the other hand, the academic institutes segment is estimated to be the fastest growing segment.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/veterinary-laboratory-testing-market-7326 

Advanced Wound Therapy Devices Market Sparkling Growth Worldwide Forecasts By 2023

 

Overview:

The global advanced wound therapy devices market size is anticipated to touch a value of USD 2,804.53 million by 2023, asserts Market Research Future (MRFR). The market can showcase 6.70% CAGR from 2018 to 2023 (forecast period).

Increasing incidence of diabetes is the primary driver of the market. Patients with diabetes have a slower healing rate and poor blood circulation which can negatively affect the immunity system. According to the Centers for Disease Control & Prevention (CDC), nearly 30.3 million in the U.S. suffer from diabetes. The advanced wound therapy devices market can expand by capitalizing on this trend and offering precise solutions.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7421 

The growing numbers of the geriatric populace will be highly beneficial to the market. This is buttressed by the estimation by the World Health Organization (WHO) which pegs the elderly populace at 1.2 billion by 2025. Furthermore, development of novel products and rapid approval by regulatory bodies is projected to propel the advanced wound therapy devices market. For instance, ConvaTec got approval for its negative pressure wound therapy (NPWT) system by the U.S. FDA in 2018. The hydrofiber gels in the system lock the exudates and bacteria and offer a separate channel for the them to flow away from the wounded region.

Segmentation Analysis:

The advanced wound therapy devices market is segmented by type and end-user.

By type, negative pressure wound therapy systems accounted for 42.9% share in 2017, followed by pressure relief devices (28.2%), hyperbaric oxygen equipment (15.2%), electric stimulation devices (7.9%), and others (5.8%). Negative pressure wound therapy systems can attain revenue close to USD 1,217.41 million by 2023 at 6.91% CAGR over the forecast period. But pressure relief devices are projected to experience the highest CAGR of 7.03% during the assessment period to accrue close to USD 805.35 million by 2023.

Among end-users, hospitals & clinics accounted for 73.7% share in 2017, followed by home care settings (14.5%), and others (11.8%). Hospitals & clinics can register close to 6.95% CAGR during the forecast period to generate close to USD 2,095.66 million by 2023. On the other hand, the home care settings segment is expected to exhibit 6.78% CAGR to touch a size of USD 408.50 million by the end of the forecast period.

Regional Analysis:

Region-wise, the advanced wound therapy devices market is segmented into Europe, Asia Pacific (APAC), Americas, and the Middle East & Africa (MEA).

The Americas are anticipated to reign as the leading region of the market owing to a mix of attractive reimbursement schemes, numerous treatment options, and prevalence of diabetes and chronic wounds. The region can accumulate close to USD 993.07 million by 2023 at 6.11% CAGR over the forecast period.

The European region is touted to register a notable growth rate owing to awareness of chronic wounds, rise in government initiatives, and awareness among healthcare providers. Presence of reputed companies such as Lohmann & Rauscher and technological advances of products can drive the regional advanced wound therapy devices market growth. The region can accrue close to USD 924.85 million by 2023 at 7.02% CAGR over the forecast period.

The APAC region is expected to be extremely lucrative for the advanced wound therapy devices market. This can be credited to high number of burn injury cases and awareness of NPWT devices. It can attain a size of USD 676.27 million by 2023 at 7.16% CAGR over the assessment period.

Competitive Analysis:

Notable player names in the advanced wound therapy devices market are Cardinal Health (U.S.), ConvaTec Inc. (U.K.), Smith & Nephew plc (U.K.), Triage Meditech Pvt. Ltd. (India), Medela AG (Switzerland), Sechrist (U.S.), Mölnlycke Health Care AB (Sweden), B. Braun Melsungen AG (Germany), DeRoyal Industries, Inc. (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), Perry Baromedical (U.S.), and KCI Licensing, Inc. (U.S.).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/advanced-wound-therapy-devices-market-7421 

The Preclinical Imaging Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights

The global preclinical imaging market size anticipated to have held a market value of USD 2.01 billion in the year 2017 and is expected to grow at a CAGR of 6.3% during the forecast period. Preclinical imaging solutions are used during the preclinical research for visualization of living animals. It is playing important role during drug development process. It is evaluating the effectiveness and safety of new treatments and describing drug distribution patterns before clinical use. preclinical imaging solutions has broad application field such as, neurology; cardiology; inflammation; infectious diseases; cancer research; functional and anatomical neuroimaging, orthopedics; and cardiac imaging.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7365  

Technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches are expected to drive the growth of preclinical imaging market. Many organization and foundation provide the funding support for the preclinical researche activity. The Alzheimer's Drug Discovery Foundation was providing the funding opportunity for preclinical study up to USD 5 million. Similarly, in 2015 Deutsches Zentrum für Herz-Kreislaufforschung e.V. (DZHK) offered Euro 6 million for the preclinical research projects. This funding supports the market growth.

Regional Analysis

Geographically, the Americas is expected to dominate the global preclinical imaging market owing to the presence of well-established players, technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches. Europe is expected to hold the second largest position in the global preclinical imaging market. Asia-Pacific is expected to be the fastest growing market owing to the increasing funding to support preclinical researches. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global preclinical imaging market.

Segmentation

The global preclinical imaging market has been segmented into modality, reagent, and region.

Based on modality, preclinical imaging market is segmented into optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, micro-CT, photoacoustic imaging system, and magnetic particle imaging systems. The optical imaging systems segment is expected to account for the largest share segment of the market in 2017.

Based on reagent, preclinical imaging market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. The preclinical optical imaging reagents segment is expected to account for the largest share segment of the market in 2017.

Key Players

Some of the prominent players in the global preclinical imaging market are Bruker Corporation (US), MR Solutions (UK), PerkinElmer Inc. (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), LI-COR, Inc. (US), Miltenyi Biotec GmbH (Germany), Aspect Imaging (Israel), and Trifoil Imaging (US).

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365  

The Cell Surface Markers Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights

The global cell surface markers industry is anticipated to hold a market value of USD 498 million in the year 2017 and is expected to grow at a CAGR of 8.4% during the forecast period. Cell surface markers or cell surface antigen work as monograms for identification and classification of cells. The proteins that are expressed on the cell surfaces often conveniently work as markers for specific types of cells.

Increasing expenditure in the advancement of healthcare technology, advancement in technology, acquisitions by companies and outlook for reduction of costs associated with disease diagnosis are expected to drive the growth in the market over the forecast period. For instance, in April 2014, Beckman Coulter, acquired Xitogen Technologies, a cytometer manufacturer. This acquisition helped Beckman Coulter to broaden its product offerings and enabled business expansion in Asia.  However, complex products and expensive instruments & reagents can restrain the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7410 

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the significant amount of research and development activities and well-developed healthcare infrastructure. According to the Organization for Economic Co-operation and Development(OECD), In 2016 united states has spent USD 464,324 million on research and development activities which is 2.7% of total GDP.  Europe is expected to hold the second largest position in the global market owing to the well-developed healthcare infrastructure. Asia-Pacific is expected to be the fastest growing market owing to the growing demand for user friendly targeted therapies. Moreover, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation

The global cell surface markers market has been segmented into product, source, cell type and application.

The market, on the basis of product, has been segmented into antibody and PCR array.

The global market, on the basis of source, has been segmented into mice, rat and others.

The global market, on the basis of cell type, has been segmented into T cells, B cells and NK cells. T cells are expected to hold the largest market share owing to high usage of them in research and diagnostics. NK cells are expected to grow at the fastest CAGR owing to increasing application of these types of cell.

The global cell surface markers market, by application, has been segmented into research, clinical and others. Research segment has been further divided into stem cell and immunology. Clinical segment is further divided into oncology and hematology.

Key Players

Some of the prominent players in the global cell surface markers market are Bio-Rad Laboratories, Inc., Abbott, Siemens Healthcare Private Limited, Beckman Coulter, Inc. , F. Hoffmann-La Roche Ltd, NIHON KOHDEN CORPORATION, Thermo Fisher Scientific, BD, Abcam plc., QIAGEN, Danaher, GenScript, Merk KGaA, BioLegend, Inc., Cell Signaling Technology, Inc., Bio-Techne and Others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/cell-surface-markers-market-7410